SCHEMBL25811835

SCHEMBL25811835

CN1CCN(CCN(C)C(=O)c2ccc3[nH]c4c(c3c2)CCCC4)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.52
MAPT P10636 6/20 0.52
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
POLB P06746 4/20 0.50
TP53 P04637 1/20 0.48
CASP1 P29466 1/20 0.48
GAA P10253 1/20 0.47
F2 P00734 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 2/20 0.45
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PARP1 P09874 1/20 0.45
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25815140 0.98 MEN1 (0.49) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25812002 0.94 KDM4E (0.54) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811968 0.94 LMNA (0.54) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811982 0.93 MAPT (0.53) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811972 0.92 LMNA (0.51) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811965 0.90 MAPT (0.52) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811720 0.88 KDR (0.49) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25815092 0.84 KDM4E (0.59) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25813810 0.82 KDM4E (0.56) LMNAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL25811277 0.80 TP53 (0.69) LMNAMAPTKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 LMNA 2606/4885MAPT 18/4885KDM4E 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.